Aditum is the Latin word for "access," and our mission is to give patients access to medicines that may not otherwise be developed.
Aditum Bio is a new model of biotech venture capital uniquely positioned to rapidly translate scientific discoveries into innovative new medicines. Aditum Bio brings together unmatched scientific and domain expertise, combined with operational capabilities. Our agile operating model enables rapid company formation, planning and execution for a new model of drug development . We target clinic-ready therapies to help underserved patient populations, rapidly forming companies and staffing them with medical and scientific experts.
Launched in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research, Dr. Mark Fishman, Aditum Bio currently manages a broad portfolio of clinical stage companies.
For more information, please visit www.aditumbio.com.
Company Details
- Employees
- 52
- Founded
- -
- Address
- 1111 Broadway,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://aditumbio.com
- HQ
- Oakland, California
Aditum Bio Questions
Aditum Bio's website is http://aditumbio.com
Aditum Bio's LinkedIn profile is https://www.linkedin.com/company/aditum-bio
Aditum Bio has
52 employees.
View email and phone details for 52
employees at Aditum Bio.
Aditum Bio's industry is
Biotechnology Research
Aditum Bio's top competitors are
Synlico Inc.,
Crystal Bio Solutions, A Member Of Crystal Pharmatech,
Henlius Usa Inc.,
Shiru,
Sonothera,
Arcadia Science,
Juvena Therapeutics,
Naderi Engineering, Inc.,
Rheosense Inc.,
Newlimit.
Aditum Bio's categories are Biotechnology Research
Aditum Bio's founding year is 2019
